ElevateBio is a creator and operator of a portfolio of innovative cell and gene therapy companies.
ElevateBio is building a facility that is intended to manufacture experimental gene and cell therapies for multiple startups.
ElevateBio was founded in 2017 by David Hallal, Mitchell H. Finer, and Vikas Sinha. The company is headquartered in Cambridge, Massachusetts, with ElevateBio BaseCamp located in Waltham, Massachusetts.
ElevateBio specializes in creating and operating a portfolio of cell and gene therapy companies to develops, manufactures, and commercializes life-transforming medicines.
ElevateBio leverages its internal bench-to-bedside expertise to accelerate the development and delivery of therapies – supported by its broad access to capital. ElevateBio portfolio companies, as well as select strategic partners are supported by ElevateBio BaseCamp in the advancement of novel cell and gene therapies.
ElevateBio’s novel business model, including BaseCamp, their centralized R&D and manufacturing organization, is structured to rapidly and efficiently build single- and multi-product cell and gene therapy companies.
ElevateBio’s investors include F2 Ventures, MPM Capital, EcoR1 Capital, Redmile Group,Vertex Ventures, Samsara BioCapital, The Invus Group and others. The company raised $170M in Series B round on March 30, 2020. This brings ElevateBio's total funding $320M to date.